STVN — Stevanato Group S.p.A.

Summary of Stevanato Group (STVN) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: EUR 273.6 million, a 10% increase at constant currency and 7% on a reported basis.
• Biopharmaceutical and Diagnostic Solutions (BDS) Segment: Revenue grew 13% to EUR 249 million, driven by high-value syringes (up over 20% year-over-year) and a 15% increase in biologics revenue.
• Engineering Segment: Revenue declined 31% to EUR 24.6 million, attributed to low backlog and slow new order intake.
• Gross Profit Margin: Increased by 30 basis points to 27.5%.
• Operating Profit Margin: Increased by 70 basis points to 14.2%.
• Net Profit: EUR 28 million; adjusted net profit increased 5% to EUR 29.6 million.
• Adjusted EBITDA: Increased 14% to EUR 65.5 million, with an adjusted EBITDA margin of 23.9%.
• Free Cash Flow: EUR 5.5 million generated in Q1 2026.

2. Strategic Updates and Business Highlights

• High-Value Solutions: Comprising 47% of total revenue, driven by demand for pre-fillable syringes and cartridges.
• Capacity Expansion: Conversion of underutilized vial lines to cartridge lines to meet rising demand, with commercial production expected soon.
• Engineering Segment Improvements: Initial margin improvements noted due to operational efficiencies from a business optimization plan.
• Growth Investments: Continued focus on scaling operations in the U.S. and Italy, with significant capital expenditures (EUR 67.6 million) directed towards growth investments.

3. Forward Guidance and Outlook

• 2026 Guidance: Revenue expected to be between EUR 1.260 billion and EUR 1.290 billion, adjusted EBITDA between EUR 331.8 million and EUR 346.9 million, and adjusted diluted EPS between EUR 0.59 and EUR 0.63.
• Market Outlook: Anticipated continued growth in the GLP1 market, with a mid-teens growth assumption for high-value solutions in 2026.

4. Bad News, Challenges, or Points of Concern

• Engineering Segment Decline: Significant revenue drop (31%) due to low backlog and slow order intake, with caution expressed regarding the pace of new orders.
• Inflationary Pressures: Rising costs for inputs and logistics noted, with potential impacts on margins and profitability.
• Tax Rate Increase: Discontinuation of a favorable tax incentive in Italy led to an increased tax rate from 24.5% to 28.6%.
• Customer Decision Delays: Lengthening sales cycles noted, impacting order intake in the Engineering segment.

5. Notable Q&A Insights

• GLP1 Revenue: Represented 21%-22% of total revenue, with growth driven primarily by commercial assets and a strong pipeline of new products.
• Engineering Segment Visibility: While some contracts are being won, the decision-making process is slower than anticipated, leading to cautious expectations for the segment's recovery.
• Cartridge Demand: Fully booked for 2026, with ongoing investments to meet future demand, indicating strong market positioning.
• Inflation Impact: Management is actively working to mitigate inflationary pressures through customer discussions and strategic pricing adjustments.

Overall, Stevanato Group reported solid growth in its biopharmaceutical segment while facing challenges in engineering, with a cautious yet optimistic outlook for the remainder of 2026.